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ABSTRACT
Objective: The UKPDS 34 and 51 showed that intensive
blood glucose control with metformin is cost-saving and
increases life expectancy in overweight type 2 diabetic
patients in the United Kingdom. Diabetes is becoming an
important health problem in urban China. This study
addresses the effects and costs of intensive blood glucose
control in this setting, aimed at supporting decision-making
on the allocation of scarce resources.
Methods: A decision analytic model was developed to esti-
mate the costs and effectiveness of intensive blood glucose
control in overweight type 2 diabetes patients in Beijing,
compared with usual care in accordance with clinical practice.
The analysis was carried out from a health-care perspective.
Results: The base-case analysis (3% discount rate) shows
that the average incremental costs of 11 years of intensive
treatment with metformin are 126.6 K RMB (16.4 K US$)
per quality-adjusted life year (QALY) gained. The incremen-
tal cost-effectiveness ratio (ICER) is sensitive to the costs of
medication alternatives for metformin in the intensive
treatment group and to the discount rate used (0%: 105.6 K
RMB (13.7 K US$) per QALY gained; 5%: 171.0 K RMB
(22.2 K US$) per QALY gained). After 20 and 30 years (life-
time) follow-up, the ICERs become increasingly favorable,
90.1 K RMB (11.7 K US$) and 74.3 K RMB (9.6 K US$),
respectively. The ICER is most sensitive to the costs of medi-
cation alternatives for metformin in the intensive treatment
group, and to the discount rate.
Conclusions: Interpretation of the ﬁndings depends on the
maximum willingness to pay for a QALY in China, which has
not ofﬁcially been deﬁned. If this would be three times the
gross domestic product per capita, a value that has been
suggested in the literature, lifetime intensive blood glucose
control is likely to be cost-effective. Our ﬁndings differ from
the UKPDS studies and emphasize that generalizing the
results of studies across countries requires considerable adap-
tation to the local context.
Keywords: cost-utility analysis, diabetes mellitus type 2,
Markov modeling, P.R. China.
Introduction
According to a national health survey carried out in
2002, 22.8% of all Chinese adults are overweight and
7.1% are obese [1]. In absolute numbers, overweight
and obesity affects 260 million Chinese, or 20% of the
total population, and these numbers are expected to
increase [2,3]. Obesity or being overweight are impor-
tant risk factor for type 2 diabetes, 90% of type 2
diabetes patients are either overweight or obese [4].
Currently, there are about 20 million diabetes patients
in China, a number that is expected to increase to 50
million in 2025 [5]. A total of 95% of all diabetes
patients are diagnosed as having type 2 diabetes [5].
Compared to a national similar survey in 1996, focus-
ing on the population of at least 20 years of age, in
2002 the prevalence of diabetes had increased from
4.6% to 6.4% in big cities and from 3.4% to 3.9% in
medium and small cities [1]. In 2002, the direct health-
care costs of type 2 diabetes were estimated to amount
18.6 billion Ren Min Bi (RMB, Chinese Currency;
1 RMB is about 0.101 EUR and about 0.125 US$)
combining all cities in China, representing 3.94% of
national health-care expenditure in China in that year
[5].
The UKPDS 34 demonstrated that, compared to
usual care, intensive blood glucose control with met-
formin decreases the risk of diabetes-related end points
in overweight diabetic patients [6]. Furthermore, the
UKPDS 51 showed that the intensive blood glucose
control with metformin is cost-saving in the United
Kingdom and extends life expectancy for overweight
type 2 diabetic patients [7]. This article examines the
generalizability of the UKPDS ﬁndings to China, to
support decision-making on the allocation of scarce
health-care resources in this country. Given the differ-
ences between the two settings, the data requirements
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[2,8] and the predominantly urban location of the
disease, the article follows a modeling approach focus-
ing on a single big city, namely the capital, Beijing. The
ﬁndings may be pertinent for use by health-care
decision-makers now that the Chinese Government
has recently published a plan to implement a health-
care insurance scheme that should cover nearly all
citizens before 2010 [9]. At the same time, this
study allows discussion and incorporation of cost-
effectiveness data in the Chinese clinical guideline for
diabetes treatment, an activity which is supported by
the research community [10].
Methods
To address the issue of the generalizability of the ﬁnd-
ings of the UKPDS 34 to the setting of Beijing, China,
a Markov model has been developed [11]. The ingre-
dients of the model are subsequently introduced, based
on a general strategy to use the scientiﬁc literature to
populate the model and, where this is impossible or
inappropriate, supplement these data with data col-
lected from clinical experts.
States and Probabilities
States of diabetes patients are distinguished on the basis
of the long-term complications of the disease. This
study takes the UKPDS 34 as a starting point, distin-
guishing 10 nonfatal disease states, of which seven are
long-term and three are temporary [12]. Patients in the
“Well”-state are deﬁned as not suffering from any
long-term complications. From this state, patients can
enter into seven different long-term disease states. If
patients suffer two or more long-term complications,
they enter the “Severe Complications” state, the ﬂoor
state. Finally, when patients die from any cause, they
enter the “Death” state, which is an absorbing state. A
1-year cycle length was applied in this study.
Patients, both men and women, had to be newly
diagnosed with type 2 diabetes, 25 to 65 years old,
overweight (>120% of ideal bodyweight), and with
fasting plasma glucose (FPG) above 6.0 m mol/l and
below 15 m mol/l without symptoms of hyperglycae-
mia when following a diet [6]. Brieﬂy, usual care policy
was aimed at maintaining FPG below 15 m mol/l (6.1–
15.0 m mol/l) and at avoiding symptoms of hypergly-
caemia. Patients could use oral agents and insulin to
control FPG. Intensive treatment policy was aimed at
obtaining near-normal FPG (i.e., <6.0 m mol/l) with
metformin. Other oral agents and types of insulin
could be added with the aim of maintaining FPG
below 6.0 m mol/l. It should be noted that at present
only 11.5% of diabetes patients meet the target of an
HbA1c level lower than 6.5% [13,14].
Based on the cohort and in- and exclusion criterion
of the UKPDS, we assume that newly diagnosed dia-
betes patents do not have any long-term complications
[15]. It is also assumed that transition probabilities are
constant over time (the Markovian assumption) [16].
Transition probabilities in the “Well” state are calcu-
lated using the UKPDS 34 study. The probability of
patients in the “Well” state and in the intensive treat-
ment arm to suffer from any complications is
regarded as a baseline probability. Clinical experts
estimated the risk ratios of suffering other complica-
tions compared with a baseline. Transition probabili-
ties in “Complication” states are derived from these
baseline values multiplied by risk ratios. It was
assumed that the transition probabilities and state
costs in each of the complication states are the same
in the two arms. The basic outline of the study is
shown in Figure 1 and the structure of the model is
shown in Figure 2.
Utilities of Health States
Given our focus on “value for money,” it is appropri-
ate to use “quality-adjusted life years (QALYs) gained”
as the principle outcome in this study [17]. The utilities
of the states are based on the UKPDS 62 [18]. Utilities
of two other states, “Complication F: renal failure”
and “Severe Complications” were derived from expert
estimates.
Costs
This study applies a health-care perspective and is
therefore limited to health-care costs. For modeling
purposes, health-care costs are distinguished in two
categories, transition (or event) costs of certain com-
plications and state (or annual) costs in different states.
Total costs are equal to the transition costs plus annual
costs. There is a number of articles dealing with health-
care expenditures of diabetes-related complications in
China [19–33]. The remainder of the required cost
data is based on estimates from eight selected experts
in Beijing. Costs of metformin are derived from pub-
lications and from Intercontinental Marketing Services
(IMS) (Norwalk, CT) data of all hospitals in Beijing,
Figure 1 The two blood glucose control policies under study: usual care versus intensive treatment. Node type: a square node represents a decision.
A node with an “M” depicts a Markov node (two arms).
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which was provided by the Chinese branch of Novo
Nordisk. Adverse events are not taken into account
since the associated costs are only a minor part of the
total costs [34].
Methodology of Expert Interviews
The interviews were carried out in the period between
July 10 and July 26, 2006. All experts were inter-
viewed individually at their hospital, seven by means
of a face-to-face interview, and one by telephone. The
experts were asked to answer questions on issues with
which they were familiar. On average, each category of
costs was based on ﬁve estimates.
Willingness to Pay for a QALY Gained
There is no documentation on the maximum willing-
ness to pay (WTP) for a QALY gained in China. The
Commission on Macroeconomics and Health of
the World Health Organization estimated that the
maximum value of one year of healthy life is about
three times the annual earnings per capita [35]. Some
studies are based on this approach [36,37], with one
speciﬁcally referring to QALYs [37]. In 2005, the gross
domestic product (GDP) per capita in Beijing was
44,969 RMB (5457 US$). Using this ﬁgure results in
the assumption that the maximum WTP for a QALY
gained in China might be about 134.9 K RMB [38].
Data Analysis
Based on the Markov model, the health economic
analyses of usual care and intensive blood glucose
control with metformin are carried out. Monte Carlo
microsimulation was used in these analyses, and the
number of trials is 10,000. Annual discount rates of
3% for both utilities and costs are applied in the base
case analysis [39]. Univariate sensitivity analyses were
performed to determine the main factors inﬂuencing
the incremental cost-effectiveness ratio (ICER). All
data were analyzed using TreeAge pro Suite 2007
(TreeAge Software, Williamstown, MA), and Excel
2003 (Microsoft, Redmond, WA). Figures were pro-
duced using SAS 9.1 (SAS, Cary, NC).
Results
Input for the Model
The transition probabilities in the “Well” state (for
both intensive blood glucose control and usual blood
glucose control) are derived from the UKPDS 34 (see
Table 1). The transition probabilities in the complica-
tion states are equal to baseline values multiplied by
ratios, which are derived from expert opinion (see
Table 2). Costs were derived from selected articles
in the literature and the remaining data are mainly
based on estimates by experts (Tables 3–6). Generally,
average unit cost estimates are used in our model. For
certain items weighed costs are used, e.g., in case of
myocardial infarction and renal failure. To simplify the
calculation, we have used a ﬁxed value of 16,961.5
RMB (2197.1 US$) to represent event costs of suffer-
ing long-term complications in any complication state
[40]. This value is arrived at by weighing all event costs
of long-term complications. Similar to this, event costs
of “Temporary Complications” and “No Complica-
tions” are 1875.8 RMB (243.0 US$), and the event
costs of all causes of death are 22,218 RMB (2878.0
US$). Utilities are mainly based on results of the
UKPDS 62 (see Table 7). Utilities in any complication
states are presented in absolute terms as well as in
terms of the absolute loss compared with the “Well”
state. Two utility values, “Complication F” (renal
failure) and “Severe Complications,” are derived from
expert opinion.
Base Case
To start with, the effects and costs of the two treatment
strategies during a period of 11 years of follow-up are
summarized in Table 8. At the end of this period, the
intensive (metformin) control strategy results in an
incremental gain of 0.25 QALYs, and the incremental
cost is 33 K RMB compared to the usual care strategy.
The associated ICER is 126.6 K RMB/QALY gained
with intensive control with metformin versus usual
care, which is a little lower than the (assumed)
maximum WTP for a QALY gained, 134.9 K RMB
Figure 2 State-transition diagram. “Well,”
“Complication” (seven states, A–G), “Severe
complications,” and “Death” represent the
Markov states. The arrows indicate pathways
between the states.
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(13.0 K Euro, 17.5 K US$). 126.6 K RMB/QALY
gained is equal to 12.1 K Euro or 16.4 K US$/QALY
gained [40].
At the end of follow-up, 11 years after initiating
treatment, the probability of being in the “Well” state
and “Death” state are 0.67 and 0.17 in the intensive
control group, respectively, compared to 0.59 and 0.23
in the usual care group, respectively.
ICE Scatterplot and the Cost-Effectiveness Acceptability
Curve (CEAC)
Each dot in the scatterplot represents a single result
from the simulation, presenting the effects and costs
of a comparator (intensive blood glucose control with
metformin) relative to a baseline (usual care) (see
Fig. 3). The ellipses represent a 95% conﬁdence ellipse
and 50% conﬁdence ellipse, respectively. The adjusted
CEAC is shown in Figure 4. In this analysis, the prob-
ability that the intervention would be cost-effective is
maximally about 0.6, and the results are sensitive to
the value of the WTP Max.
Sensitivity Analyses
Without discounting effects and costs, the intensive
(metformin) control strategy leads to 0.28 QALYs
gained, and the associated ICER is 105.6 K RMB/
QALY gained, equal to 10.1 K EUR/QALY gained, or
13.7 K US$/QALY gained [40]. When a 5% discount
rate of both costs and QALYs is applied, the intensive
(metformin) control strategy leads to a gain of 0.20
QALYs, the ICER is then 171.0 K RMB/QALY gained,
equal to 16.4 K Euro/QALY gained, or 22.2 K US$/
QALY gained [40]. Other medicines’ costs in the inten-
sive treatment (metformin) group range from 1000 to
8000 RMB. Applying these values in a sensitivity
analysis results in ICERs ranging from 46 K to 332 K
RMB/QALY gained, so the ICER is most sensitive to
this particular cost variable. The costs of General Dia-
betes Management ranged from 500 to 5000 RMB.
Using these extreme values, the average ICER rangesTa
bl
e
1
M
at
ri
x
of
tr
an
si
tio
n
pr
ob
ab
ili
tie
s
fr
om
th
e
“W
el
l”
st
at
e
to
th
e
ot
he
r
st
at
es
in
th
e
m
od
el
Tr
an
si
tio
n
fr
om
W
el
ls
ta
te
To
C
om
A
:
N
on
fa
ta
lM
I
C
om
B:
H
ea
rt
fa
ilu
re
C
om
C
:
A
ng
in
a
C
om
D
:
N
on
fa
ta
ls
tr
ok
e
C
om
E:
A
m
pu
ta
tio
n
C
om
F:
R
en
al
fa
ilu
re
C
om
G
:
Bl
in
d
in
on
e
ey
e
Se
ve
re
co
m
pl
ic
at
io
ns
D
ea
th
In
te
ns
iv
e
ca
re
0.
00
65
36
99
2
0.
00
30
01
44
4
0.
00
57
22
21
1
0.
00
16
38
27
0
0.
00
16
38
27
0
0.
00
05
46
38
8
0.
00
32
73
85
5
0.
00
00
00
00
0
0.
01
36
44
00
0
U
su
al
ca
re
0.
00
90
54
42
3
0.
00
38
58
19
5
0.
00
49
90
12
3
0.
00
36
31
65
5
0.
00
20
44
43
2
0.
00
04
54
68
0
0.
00
29
51
72
6
0.
00
00
00
00
0
0.
02
01
86
13
0
C
om
,c
om
pl
ic
at
io
n;
M
I,
m
yo
ca
rd
ia
li
nf
ar
ct
io
n.
Table 2 Matrix of transition probabilities in complication states
(both treatment arms)
Transition from
complication state
To
Severe
complication state Death
Complication A: nonfatal MI 0.053868250 0.047207379
Complication B: heart failure 0.074883354 0.062761255
Complication C: angina 0.084070055 0.039566878
Complication D: nonfatal stroke 0.073175883 0.045433691
Complication E: amputation 0.088909217 0.043932879
Complication F: renal failure 0.103493363 0.065490005
Complication G: blind in one eye 0.068375951 0.034928003
Severe complications* 0.103092619 0.063579880
*Patients with severe complications transiting to “Severe complications” here means
that patients suffer another one or two long-term events in a single cycle.Although
the state does not change, the events will incur costs,which are included in the model.
MI, myocardial infarction.
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from 131 K to 161 K RMB/QALY gained. “Other
medicines” costs in the usual care group ranged from 0
to 3000 RMB. Using these values the ICER varies from
76 K to 165 K RMB/QALY gained. The costs of met-
formin range from 113 to 1918 RMB. Based on these
extreme values, the ICER ranges from 106 K to 170 K
RMB/QALY gained. All state costs and event costs are
tested as well, but these costs only have little inﬂuence
on the ICER. The utility of the “Well” state is changed
from 0.6 to 1 in the sensitivity analysis. The ICER
ranges from 114 K to 182 K RMB/QALY gained. The
incremental effectiveness increases from 0.18 QALY
gained to 0.28 QALY (more than a 50% increase)
gained with the increase of the utility value for the
“Well” state from 0.6 to 1.
Second, we calculated lifetime costs and effective-
ness of both treatment strategies. It was assumed that
transition probabilities between states are constant
over time. After 20 years, the intensive (metformin)
blood glucose control strategy leads to 0.57 QALYs
gained, and the associated ICER is 90.1 K RMB/QALY
gained or 11.7 K US$/QALY gained. And after
30 years, the intensive (metformin) blood glucose
control strategy leads to 0.94 QALYs gained with an
associated ICER of 74.3 K RMB/QALY gained, or
9.6 K US$/QALY gained in 30 years.
Conclusion and Discussion
The results of the study show that lifetime intensive
blood glucose control with metformin in overweight
type 2 diabetes patients is likely to be cost-effective in
Beijing if a maximumWTP for a QALY gained of three
times the GDP per capita would serve as the principle
criterion for decision-making. Although the estimates
of QALYs gained and the associated ICERs at 20 or
30 years of follow-up are by necessity associated with
a relatively high degree of uncertainty, there is a clear
tendency toward increased cost-effectiveness of the
intensive (metformin) control strategy with a longer
time horizon. The sensitivity analysis showed that
“other medicine’s costs” in the intensive control
(metformin) group is the most important variable
inﬂuencing the ICER. Given the regular introduction
of new pharmaceuticals in treatment of diabetes, this
adds considerably to the uncertainty associated with
Table 3 Costs (RMB) of General Diabetes Management
Name
Unit costs in ofﬁcial
documents [19]
Unit costs
(expert opinion)
Average (range)
Value used
in the model
Frequency of use/
application per year
Average (range) Costs
Education and consultation 5–10 5.2 (0–10) 7.5 10.4 (1–24) 78.0
Visiting doctors/GPs 5–10 5.6 (4–9.5) 7.5 17.3 (8.5–24) 129.8
Monitoring blood glucose 4 5.6 (5–8) 4 155.2 (24–260) 620.8
Testing blood glucose 4 8 (8–8) 4 21.6 (18–24) 86.4
Testing HbA1c 25–70 63.8 (50–74) 63.8 4 (4–4) 255.2
Testing liver function >20 45 (15–100) 45 2.1 (1.5–3) 94.5
Serum lipids test 21–128 117.5 (35–200) 117.5 1.8 (1.5–2) 211.5
Urine routine test 6–35 8 (8–8) 8 13.5 (12–15) 108.0
Renal function test >20 52.5 (35–65) 52.5 1.75 (1.5–2) 91.9
Screening for foot diseases >10 176.7 (90–240) 176.7 1.5 (1–2) 265.1
Screening for eye diseases >10 23.3 (10–50) 23.3 1.6 (1–2) 37.3
Screening for microalbuminuria 70 46.7 (20–70) 70 4.4 (1–12) 308.0
Subtotal 2286.4
GP, general practitioner.
Table 4 Costs (RMB) of drugs and induced costs in the two treatment arms
Resource Daily cost
Daily cost
(IMS)*
Value used
in the model
Costs
(average) Range
Annual
costs
Metformin in the intensive treatment group 3.16 (1.57–5.52) [20] 2.9 3.16 1154
Additional tests related to metformin† 0
Other medicines’ costs in the intensive treatment
group (expert opinion)‡
3380 (700–7800)
Additional tests in the intensive treatment group 0
Subtotal 4534
Other medicines’ costs in the usual care group
(expert opinion)‡
740 (0–3000)
Additional tests in the usual care group 0
Subtotal 740
*Based on weighed market share, and a daily dose of 1500 mg or 2550 mg.
†The test for monitoring drug-induced adverse effects.
‡To obtain near-normal FPG (i.e., <6.0 m mol/l) or <15.0 m mol/l, oral agents and different types of insulin will be added.
FPG, fasting plasma glucose; IMS, Intercontinental Marketing Services.
CUA of Type 2 Diabetes in Beijing S27
the ICER. The cost-effectiveness ratio was also sensi-
tive to the costs of metformin, “other medicine’s costs”
in the usual care group, the discount rate, and the
utility value of the “Well” state. Most analyses indicate
a potential for the intervention to be cost-effective, but
the study does not allow for deﬁnitive conclusions.
The Model
The model that we developed was applied to assess
both the 11-year follow-up and the lifetime effects and
costs of the interventions studied. The former was
chosen to allow a comparison with the UKPDS 34
study, the latter was chosen as it represents the recom-
mended approach for modeling studies of chronic
disease to be most useful for policymaking purposes.
Other modeling studies have presented lifetime health
effects and costs of diabetes treatment as well [41].
Any model is a simpliﬁcation of reality. And although
we have tried to go beyond minimum requirements,
the model in our study does not include all complica-
tions, e.g., diabetic foot (or foot ulceration) has not
been included. In theory, health economic studies
Table 5 Transition (event) cost (RMB) of complications
Event
Costs in literature
or ofﬁcial document
Costs (expert opinion)
Average (range)
Value used
in the model
Fatal myocardial infarction 5,645–66,430 [21–24] 63,100 (10,000–130,000) 36,037.5
Nonfatal myocardial infarction 5,645–66,430 [21–24] 63,100 (10,000–130,000) 36,037.5
Sudden death 3,825 (800–7,500) 3,825
Heart failure 15,750 (8,000–25,000) 15,750
Angina 9,250 (4,000–15,000) 9,250
Fatal stroke 5,695–18,004 [21,22,25–27] 16,750 (10,000–30,000) 11,849.5
Nonfatal stroke 5,695–18,004 [21,22,25–27] 16,750 (10,000–30,000) 11,849.5
Death from peripheral vascular disease 16,521 [28] 18,000 (6,000–30,000) 16,521
Amputation 10,830–20,547 [28–31] 20,750 (10,000–30,000) 15,688.5
Death from renal disease 16,219 [28] 23,333 (10,000–40,000) 16,219
Renal failure* 0 0
Retinal photocoagulation 10,366 [28,31] 4,000 (1,000–7,000) 10,366
Vitreous hemorrhage 10,366 [28] 6,250 (5,000–7,500) 10,366
Blind in one eye 10,366 [28] 6,000 (6,000–6,000) 10,366
Cataract extraction 10,366 [21,28] 8,250 (6,500–10,000) 10,366
Death from hyperglycemia 6,000 (4,000–7,500) 6,000
Death from hypoglycemia 4,667 (3,000–7,500) 4,667
Fatal accident 5,167 (1,500–8,000) 5,167
Death from cancer 25,625 (6,500–50,000) 25,625
Death from any other speciﬁed cause 9,500 (8,500–10,000) 9,500
Death from unknown cause 7,500 (5,000–10,000) 7,500
Suffering long-term complications in complication states† 16,961.5
Suffer temporary complications or not suffering complications
in complication states‡
1,875.8
Death in complication states§ 22,218
*Annual costs are counted here. So, there are no event costs.
†We weigh the costs of long-term complications.
‡We weigh the costs of temporary complications and no complications.
§We weigh the costs of all causes of death.
Table 6 State (annual) costs (RMB) of complications
State name Costs in literature
Costs (expert opinion)
Average (Range)
Value used
in the model
Complication A: nonfatal MI 17,521–47,225 [31] 13,120 (7,500–25,000) 32,873
Complication B: heart failure 10,887 [31] 13,500 (7,000–35,000) 10,887
Complication C: angina 8,576 [31] 11,900 (7,500–25,000) 8,576
Complication D: nonfatal stroke 18,405 [31] 9,875 (7,000–15,000) 18,405
Complication E: amputation 10,998–14,012 [31] 12,000 (5,000–25,000) 12,505
Complication F: renal failure* Hemeodialysis (HD) 75,865–98,204 106,650 (98,500–114,800) 102,000
Peritoneal dialysis (CAPD) 76,775–84,141 99,150 (92,000–10,630)
Kidney transplant (KT) 150,107 (First year)
54,078 (second year) [32,33]
Complication G: blind in one eye† 34,125 (blind in two eyes) [31] 6,500 (5,000–10,000) 8,000
Severe complications With macro- and microvascular complication: 38,580 [31] 26,250 (15,000–30,000) 38,580
Death 0 0
*We weigh the costs of three main treatment alternatives, haemeodialysis (70%), peritoneal dialysis (20%), and kidney transplantation (10%).The differences in costs in the ﬁrst
year and the second year are relatively modest.To simplify the calculation, we apply a ﬁxed value of 102,000 RMB.
†Based on expert opinion, the average costs are 6500 RMB. But the costs of general diabetic management plus intensive blood glucose control are nearly 7000 RMB. Due to this
and because the highest value of the estimates is 10,000 RMB, we decided to apply an estimate of 8000 RMB here.
MI, myocardial infarction.
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should record all consequences of interventions and we
know that diabetes can induce many long-term com-
plications. But it is nearly impossible to follow up and
register all of these in one clinical trial, and the UKPDS
34 only focused on a limited number of complications
as end points. Basically, severe long-term complica-
tions are regarded as end points and minor ones are
ignored in the UKPDS 34. For example, renal disease
has four stages, but only the last stage, renal failure,
was deﬁned as an end point in this study. Because of
limitations like these, we may have underestimated the
total costs of treatment in both arms during follow-up.
The Role of Experts
In this study, estimates provided by eight clinical
experts served as an important source of input for the
model, and this may have introduced bias. All experts
were interviewed individually, we did not inform the
interviewees about other experts’ estimates as part of
the process because we were most interested in collect-
ing their independent judgments. We dealt with the
variety in responses by using the average value of each
estimate provided and by including the ranges in the
sensitivity analyses. We are aware of the fact that inter-
views are not the only method available to collect
expert data. Examples of other methods for soliciting
expert opinion include, e.g., the Delphi method and
other formal consensus development methods, which
have been widely used in the USA and the EU [42].
Ideally, of course, we would not have needed any
expert opinion at all, but we were forced to use this
approach due to a paucity of relevant, up to date and
reliable data in the literature.
The Choice for Beijing as the Relevant Setting for
the Study
Why was the study limited to a single city in China?
First, at a general level, the choice for an urban setting
can be justiﬁed by the fact that the prevalence of diabe-
tes increases most rapidly in China’s big cities. Second,
the tremendous differences in economic development
across China prevent using national level data, favoring
a choice for a speciﬁc settingwith relatively high-quality
documentation. Third, although there are important
differences between the patient population in the UK
and China as a whole, these may not be as prominent
when focusing on Beijing alone. To illustrate this latter
point, life expectancy in the UK is about 5 or 6 years
higher than in China in general [2,8] but, based on data
from 2000, these differences were markedly reduced
when speciﬁcally comparing the life expectancy of men
and women in Beijing and the UK (Beijing: 74.3 [men],
78.0 [women]; UK: 74.7 [men], 79.7 [women]) [2].
Generalizability of the Findings to Other Cities in China
One of the consequences of the regional differences in
economic development in China is that data collected
in different regions of the country can hardly be gen-
eralized to the national level [2]. Clearly, the potential
Table 7 State utility values based on UKPDS 62* [18]
State name
Value loss after the
events (range)
State utility
values
Well: no long-term complication
(metformin group)
0 0.785
Well: no long-term complication
(usual care group)
0 0.785
Complication A: nonfatal MI -0.055 0.73
Complication B: heart failure -0.108 0.677
Complication C: angina -0.09 0.695
Complication D: nonfatal stroke -0.164 0.621
Complication E: amputation -0.28 0.505
Complication F: renal failure† -0.21 (-0.082–0.35) 0.575
Complication G: blind in one eye -0.074 0.711
Severe complications† -0.27 (-0.084–0.4) 0.518
Death 0
*The UKPDS 62 used the EQ-5Q, and a Tobit Model in its estimates of utilities, with
a mean tariff of 0.785.
†Estimated by experts.
Intensive blood glucose control does not inﬂuence utility values here.
MI, myocardial infarction.
Table 8 Main results of cost-utility analyses
Strategy
Cost
(RMB)
Incremental
costs Effectiveness
Incremental
effectiveness C/E
Incremental
C/E (ICER)
Usual care 56 K 6.59 QALY 8.6 K
Intensive (metformin) 88 K 32 K 6.84 QALY 0.25 QALY 12.9 K 126.6 K
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
Figure 3 ICE scatterplot of intensive blood glucose control (metformin)
versus usual care. ICE, incremental cost-effectiveness; QALY, quality-
adjusted life year.
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for generalizing the results of this study is limited to
major urban areas. A number of considerations seem
important here. First, citizens in only a few other
regions, like Shanghai and Tianjin, are known to have
a similar life expectancy as those living in Beijing,
which is about ﬁve years longer compared to the
average citizen [2]. In other major cities, e.g., Guang-
dong and Shenzhen, data on life expectancy are
lacking. We stress this point because life expectancy,
age-related morbidity/mortality rates, transition prob-
abilities and QALYs gained are all linked. Third, and
related to the former point, clinical practice and its
variations are associated with levels of economic devel-
opment and prosperity. Chinese national statistical
reports show that the national annual expenditure per
capita on medicine and medical services was 430 RMB
(55.7 US$) for urban residents in 2002, but that this
ﬁgure is 950 RMB (123.0 US$) for Beijing, which
ranks highest in China [2]. Compared with the
national level, Shanghai and Tianjin also have higher
per capita expenditure on medicine and medical ser-
vices than the national average, conﬁrming their status
as cities where the ﬁndings of this study might apply.
The International Level
Internationally, a few economic evaluations have been
carried out which are linked to the UKPDS 34, includ-
ing the UKPDS 51, UKPDS 72, and an application
of the UKPDS 34 to Switzerland [6,7,13,43]. Those
studies all report similar results in the sense that the
intensive blood glucose control strategy dominates
usual care (meaning that intensive treatment is less
costly and more effective). The results for China are
essentially different from those in Western countries,
with increased effectiveness associated with increased
costs of the intervention, but with as yet limited gen-
eralizability. It seems that there still is a long way to go
before results obtained in Western countries, no matter
the sophistication of the underlying models, can be
reliably transferred to (parts of) developing countries
like China. With this study we have tried to contribute
to this development.
We thank Novo Nordisk for providing IMS data and for
assisting in correcting the English language in this article. We
would also like to express our appreciation for the assistance
we received from Prof. Terkel Christiansen, Prof. Anders
Green, and Andy Sheldon (TREEAGE). A special thanks goes
to all clinical experts in Beijing who were willing to partici-
pate in an interview.
Source of ﬁnancial support: The University of Southern
Denmark supported this study with a small grant for travel-
ing and the purchase of software.
References
1 Ministry of Health P. R. China (MHC). The Nutrition
and Health Status of the Chinese People, 2004
[internet]. Beijing: MHC, 2006. Available from: http://
www.moh.gov.cn/PUBLIC/open.aspx?n_id=8646 (in
Chinese) [Accessed August 2, 2006].
2 National Bureau of Statistics of China (NBSC). China
Statistical Yearbook 2003 (Issue No. 22). Beijing:
China Statistics Press, 2003. (in Chinese).
3 Ma GS, Li YP, Wu YF, et al. The prevalence of body
overweight and obesity and its changes among
Chinese people during 1992 to 2002. Chin J Prev Med
2005;39:311–5 (in Chinese).
4 Albu J, Pi-Sunyer FX. Obesity and diabetes. In: Bray
GA, Bouchard C, James WPT, eds, Handbook of
Obesity. New York: M. Dekker, 1998.
5 Tang L, Chen XB, Chen HY, et al. The economic
burden of type 2 diabetes mellitus and its complica-
tions in the cities of China. Chin Health Econ Mag
2003;22:21–3 (in Chinese).
6 UK Prospective Diabetes Study Group. Effect of inten-
sive blood glucose control policy with Metformin on
complications in type 2 diabetes patients (UKPDS 34).
Lancet 1998;352:854–65.
Figure 4 Adjusted cost-effectiveness accept-
ability curve (willingness to pay from 0 to 200 K
RMB).
S30 Xie and Vondeling
7 Clarke P, Gray A, Adler A, et al. Cost-effectiveness
analysis of intensive blood-glucose control with met-
formin in overweight patients with type II diabetes
(UKPDS 51). Diabetologia 2001;44:298–304.
8 World Health Organization (WHO). The World
Health Report 2000. Geneva: WHO, 2000.
9 MHC. Guidelines of Developing Primary Health Care
Service in Urban Areas (State Council of the People’s
Republic of China) 2006 [Internet]. Beijing: MHC,
2006. Available from: http://www.moh.gov.cn/public/
open.aspx?n_id=11441 (in Chinese) [Accessed August
2, 2006].
10 Mason J, Eccles M, Freemantle N, et al. A framework
for incorporating cost-effectiveness in evidence-based
clinical practice guidelines. Health Policy 1999;47:
37–52.
11 Briggs A, Sculpher M. An introduction to markov
modelling for economic evaluation. PharmacoEco-
nomics 1998;13:397–409.
12 Palmera AJ, Sendia PP, Spinasb GA. Applying some
UK Prospective Diabetes Study results to Switzerland:
the cost-effectiveness of intensive glycaemic control
with metformin versus conventional control in over-
weight patients with type-2 diabetes. Schweiz Med
Wochenschr 2000;130:1034–40.
13 Pan CY, Cooperative group in China. A survey of
diabetes management in China—Gap between guide-
line and practice. Section Endocrinol Foreign Med Sci
2005;25:174–8 (in Chinese).
14 Compilation Group of Chinese Guideline for Dia-
betes Prevention and Treatment. Chinese Guideline
for Diabetes Prevention and Treatment. Beijing:
Medical Publisher of Peking University, 2004. (in
Chinese).
15 UK Prospective Diabetes Study Group. Intensive
blood glucose control with sulphonylureas or insulin
compared with conventional treatment and risk of
complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998;352:837–53.
16 Hunink MGM, Glasziou PP, Siegel JE, et al. Decision
Making in Health and Medicine: Integrating Evidence
and Values. Cambridge: Cambridge University Press,
2001.
17 ADA consensus Panel. Guidelines for computer mod-
eling of diabetes and its complications. Diabetes Care
2004;27:2262–5.
18 Clarke P, Gray A, Holman R. Estimating utility values
for health states of type 2 diabetic patients using the
EQ-5D (UKPDS 62). Med Decis Making 2002;22:
340–9.
19 The World of Medical Sources. Medical Service
Charge Criteria of Health Care Institutes in Beijing
[Internet]. Beijing: 39kf.com, 2007. Available from:
http://www.39kf.com/treatment/manual/medical-
charge-standard/index2.shtml (in Chinese) [Accessed
April 12, 2007].
20 Wang QH, Yang C, Yuan J. Investigation and analyses
of oral blood-glucose lowing agents. Guandong
Pharm J 2005;15:56–9 (in Chinese).
21 MHC. The Average In-Patient Medical Expenditures
of 30 Diseases in 2004, 2005 [Internet]. Beijing:
MHC, 2006. Available from: http://www.moh.gov.cn/
statistics/on_net_ﬁle_2005/s72.htm (in Chinese)
[Accessed August 2, 2006].
22 Beijing Municipal Health Bureau. Inpatient medical
expenditures of patients with health insurance for
some diseases in city or MHC levels hospitals in
Beijing in 2004 (Part One). 2006: (This is an unpub-
lished ofﬁcial report, in Chinese).
23 Yin L, Li GP, Li J, et al. Comparison of direct PCI and
thrombolytic therapy (Urokinase) for acute myocar-
dial infarction: healing effect and cost-effectiveness
results. Chin J Crit Care Med 2003;23:515–8
(in Chinese).
24 Cui YJ, Liu QG, Wang LH. An analysis of medical
expenditures of inpatients with acute MI. Chin Hosp
2004;8:71–3 (in Chinese).
25 Hu SL, Gong XG. Economic Burden of ischemic
stroke in China. Chin Health Econ Mag 2003;22:
18–20 (in Chinese).
26 Wang M, Liu KJ, Wang DJ. The current situation and
issues on direct burden of intracerebral hemorrhage
in China. Chin Health Econ Mag 2005;24:43–6
(in Chinese).
27 Sun RF, Li YD, Wang Y, et al. Comparison of medical
expenditures with and without health insurance
for ischemic stroke. Chin J Health Stat 2005;22:305
(in Chinese).
28 Xia SJ, Yang L, Hu SL. Analysis on the inpatient
expenditure of Diabetes Mellitus and its complica-
tions. Chin Hosp Manage 2004;24:40–2 (in Chinese).
29 Wang YZ, Xu ZR, Hu CW. Clinical features and
hospitalisation costs in diabetic patients with foot
problems. Chin J Mult Organ Dis Elderly 2003;2:
271–4 (in Chinese).
30 Wang AH, Zhao D, Li Q, et al. A multi-center survey
on the diabetic foot and medical economics in China.
Chin J EndocrinolMetab 2005;21:496–9 (in Chinese).
31 Chen X, Tang L, ChenH, et al. Assessing the impact of
complications on the costs of Type 2 diabetes in urban
China. Chin J Diabetes 2003;11:238–41 (in Chinese).
32 Wen JQ, Ji YL, Zheng ZH, et al. Cost-effectiveness
analysis of Haemeodialysis, CAPD and kidney
transplantation. Chin J Nephrol 2005;21:616–9
(in Chinese).
33 Wang JJ, Ye L, Hu SL, et al. Disease burden and
dialysis therapy. Chin Health Resources 2006;9:68–9
(in Chinese).
34 Ramsdell JW, Braunstein SN, Stephens JM, et al. Eco-
nomic model of ﬁrst-line drug strategies to achieve
recommended glycaemic control in newly diagnosed
type 2 Diabetes Mellitus. PhamacoEconomics 2003;
21:819–37.
35 Commission on Macroeconomics and Health of
WHO. Report on Macroeconomics and Health:
Investing in Health for Economic Development.
Geneva: WHO, 2001.
36 Murray CJ, Lauer JA, Hutubessy RCW, et al. Effec-
tiveness and costs of interventions to lower systolic
blood pressure and cholesterol: a global and regional
analysis on reduction of cardiovascular-disease risk.
Lancet 2003;361:717–25.
37 Borgstrom F, Johnell O, Kanis JA, et al. At what hip
fracture risk is it cost-effective to treat? International
CUA of Type 2 Diabetes in Beijing S31
intervention thresholds for the treatment of
osteoporosis. Osteoporos Int 2006;17:1459–71.
38 Bureau of statistics of Beijing. Report of Economic
and Societal Development Statistics of ‘the Tenth
Five-Year Plan’ of Beijing in 2005. 2006 [Internet].
Beijing: National Bureau of Statistics of China, 2006.
Available from: http://www.stats.gov.cn/tjgb/ndtjgb/
dfndtjgb/t20060125_402307649.htm (in Chinese)
[Accessed September 30, 2006].
39 Drummond M, Sculpher MJ, Torrance GW, et al.
Methods for the Economic Evaluation of Health Care
Programs (3rd ed.). Oxford: Oxford University Press,
2005.
40 Industrial & Commercial Bank of China (ICBA).
RMB Exchange Spot Rates, 2007 [Internet]. Beijing:
ICBA, 2007. Available from: http://www.icbc.com.cn/
e_other/quotation.jsp [Accessed April 12, 2007].
41 Niessen LW, Dijkstra R, Hutubessy RCW, et al. Life-
time health effects and costs of diabetes treatment.
Neth J Med 2003;61:355–64.
42 Barker C. The Health Care Policy Process. New Delhi:
Sage Publications, 1996.
43 Clarke PM, Gray AM, Briggs A, et al. Cost-utility
analyses of intensive blood glucose and tight blood
pressure control in type 2 diabetes (UKPDS 72).
Diabetologia 2005;48:868–77.
S32 Xie and Vondeling
